<p><strong>TG Therapeutics Inc</strong> (NASDAQ:TGTX) shares are trading higher on Wednesday as positive topline Phase 1 data for a subcutaneous version of BRIUMVI fuels fresh optimism around pipeline expansion. Here’s what investors need to know.</p>



<ul>
<li>TG Therapeutics stock is at critical resistance. What’s driving TGTX to record levels?</li>
</ul>



<h2>What Is Driving TG Therapeutics Stock Higher?</h2>



<p>The company on Tuesday reported positive Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in myasthenia gravis, with 82% of subjects hitting a minimal clinically important difference in MG-ADL and a mean improvement of over four points. Management also said it plans to start a Phase 2 trial enrolling about 120 patients, aiming to pair rapid symptom control with longer-term disease modification.</p>



<p>In a related BRIUMVI program, TG Therapeutics previously posted positive topline results in May from the Phase 3 ENHANCE trial for a consolidated single-infusion initiation regimen in relapsing forms of multiple sclerosis, and it's targeting a supplemental FDA filing in the second half of 2026.</p>



<h2>Critical Price Levels To Watch For TGTX</h2>



<p>Wednesday's surge is pushing the stock further above its trend gauges: it's trading about 20.5% above the 20-day SMA ($39.86) and 45.9% above the 200-day SMA ($32.91), which is the kind of &#34;extended&#34; posture that can invite volatility even in a bull trend. The bigger-picture structure is still constructive, with the 20-day SMA above the 50-day SMA and a golden cross (50-day above 200-day) that formed in April.</p>



<figure class="wp-block-image size-large"><img width="1024" height="512" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/06/10110213/image-247-1024x512.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/06/10110213/image-247-1024x512.png"/></figure>



<figure class="wp-block-image size-large"><img width="1024" height="512" src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/06/10110213/image-247-1024x512.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://editorial-assets.benzinga.com/wp-content/uploads/2026/06/10110213/image-247-1024x512.png"/></figure>



<p>For momentum, MACD is the cleaner lens right now: it's above its signal line with a positive histogram, which points to improving upside pressure versus the prior downswing. Practically, that means dips are more likely to get bought while MACD stays in that posture, but the stock's distance from the moving averages raises the odds of sharp pullbacks if sentiment cools.</p>



<ul>
<li><strong>Key Resistance</strong>: $48.67 — a fresh breakout zone after clearing the prior 52-week high ($44.65), making the current area the nearest &#34;prove it&#34; level </li>



<li><strong>Key Support</strong>: $39.86 — near the 20-day SMA, a logical first spot where trend buyers may look to defend the move</li>
</ul>



<h2>What Is TG Therapeutics And Its Business Model?</h2>



<p>TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. It already has FDA approval for BRIUMVI (ublituximab-xiiy) to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.</p>



<p>It also has approvals outside the U.S. for BRIUMVI in RMS patients with active disease defined by clinical or imaging features. That matters for Wednesday's move because positive data in myasthenia gravis (a new indication) can expand the product's long-term opportunity set beyond MS, which is often what drives step-changes in biotech valuations.</p>



<h2>TG Therapeutics Benzinga Edge Scorecard Analysis</h2>



<p>Below is the Benzinga Edge scorecard for TG Therapeutics, highlighting its strengths and weaknesses compared to the broader market:</p>



<ul>
<li><strong>Momentum</strong>: Bullish (Score: 86.62) — The stock is showing strong relative strength, consistent with a trend-driven breakout.</li>



<li><strong>Value</strong>: Weak (Score: 27.49) — Valuation looks less compelling versus peers, so execution and continued growth matter more to justify the price.</li>
</ul>



<p><strong>The Verdict:</strong> TG Therapeutics’s Benzinga Edge signal reveals a momentum-driven setup with price action doing most of the heavy lifting. If momentum cools, the weaker Value score suggests the stock may be less forgiving on any disappointment, making support levels more important for risk control.</p>



<h2>TGTX Stock Price Movement On Wednesday</h2>



<p><strong>TGTX Stock Price Activity:</strong> TG Therapeutics shares were up 9.50% at $44.49 at the time of publication on Wednesday, according to Benzinga Pro data.</p>



<div>


<p>
<strong>
Read Also:

Anthropic's Growth Is Exploding. Palantir Says That's Exactly The Problem
</strong>
</p>


</div>


<p><em>Image: Shutterstock</em></p>

TGTX

<p>TG Therapeutics (NASDAQ: TGTX) shares surged 9.50% on Wednesday following positive Phase 1 data for a subcutaneous version of BRIUMVI in myasthenia gravis. The results, showing significant clinical improvement, have fueled optimism regarding pipeline expansion and upcoming Phase 2 trials. This development aims to broaden the drug's application beyond its current approval for multiple sclerosis, driving strong momentum despite the stock trading at extended levels relative to key moving averages.</p>

TG Therapeutics Stock Is Surging Today: What's Driving The Action?